
Jim Scopa
Venture Partner
| Healthcare
| Location: United States
Jim is a Venture Partner at OneVentures, serving on the investment committee of Healthcare Fund III, a board member of BiVACOR, and an advisor to the healthcare team.
An experienced venture capitalist and former healthcare investment banker, Jim brings expertise in the biopharmaceuticals, medical devices, and diagnostics sectors of life sciences.
He previously served as a Managing Director and member of the Investment Committee at MPM Capital, a US$2.6 billion global venture fund focused on early-stage life sciences. He has 18 years of experience in healthcare investment banking, advising emerging growth companies on financings and strategic transactions as a Managing Director at Deutsche Bank and Thomas Weisel Partners.
Jim has served on the boards of DICE Pharmaceuticals (sold to Eli Lilly for $2.4 billion in 2023), Semma Pharmaceuticals (sold to Vertex for $950 million in 2019), and True North Therapeutics (sold to Bioverativ for $825 million in 2017).
He was appointed a Fellow at the Distinguished Career Institute at Stanford for 2017–2018. He holds an MBA, JD (Harvard).
| MBA, JD (Harvard)